Ovarian Cancer Recurrent Clinical Trial
Official title:
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP rintatolimod (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (IVP) for patients with recurrent platinum-sensitive ovarian cancer (OC).
Patients will receive a total of six treatment cycles, at 3-week intervals. The study will use an IP neoadjuvant approach (IP chemoimmunotherapy of cisplatin with IP rintatolimod and IV infusion of pembrolizumab), followed by interval cytoreduction (usually laparoscopically) of residual tumor. Cytoreduction will occur approximately 4 weeks after the fourth treatment cycle. Post-surgery the investigators will consolidate with 2 additional courses of same chemo-immunotherapy regimen. Catheter will be removed 12 weeks after the last treatment. All surgical procedures, if done laparoscopically, are outpatient and will yield up to three serial biopsies of the tumor sites: 1) at catheter placement; 2) at interval cytoreduction which consists of removal of any visible tumor sites and the site biopsied initially whether tumor is present or not; 3) at catheter removal, when site of first tumor biopsy will be re-biopsied for pathologic response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06014528 -
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03717610 -
Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
|
N/A | |
| Active, not recruiting |
NCT04175470 -
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT03983226 -
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
|
Phase 2 | |
| Recruiting |
NCT05095558 -
Microtransplantation for Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03657966 -
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06102707 -
The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients
|
N/A | |
| Terminated |
NCT03162562 -
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
|
Phase 1 | |
| Withdrawn |
NCT04149145 -
Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT01332656 -
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
|
Phase 2 | |
| Completed |
NCT01111903 -
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03827837 -
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT05990192 -
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
|
Phase 2 | |
| Completed |
NCT01485848 -
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT03681548 -
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
|
Phase 1 | |
| Recruiting |
NCT04072263 -
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
|
Phase 1/Phase 2 |